Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23526026 | 0.79 | SMARCA2 (0.35) | SMARCA2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL23608697 | 0.77 | SYK (0.39) | SMARCA2 | |
| SCHEMBL23580230 | 0.72 | IGF1R (0.39) | SMARCA2ALDH1A1 | |
| SCHEMBL17292918 | 0.72 | SMARCA2 (0.66) | SMARCA2 | |
| SCHEMBL23060373 | 0.71 | BACE1 (0.39) | S1PR2GRM4TP53 | |
| SCHEMBL2093377 | 0.66 | EGFR (0.50) | HPGDGRM4 | |
| SCHEMBL16992910 | 0.66 | LMNA (0.54) | ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL23831580 | 0.66 | ALDH1A1 (0.52) | ALDH1A1HSD17B10S1PR2 | |
| SCHEMBL15880770 | 0.66 | GRM5 (0.48) | SMARCA2TP53 | |
| Ammonia Solution, Strong SCHEMBL20873165 | 0.65 | GPR35 (0.42) | S1PR2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2021134004-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRODINGER, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | MALT1, FKBP1B, FKBP1A | SMARCA2 3538/4885ALDH1A1 2190/4885KDM4E 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.